Novavax, Aifa green light for the Nuvaxovid protein vaccine

Aifa green light for the Nonovax vaccine. The Technical Scientific Commission (Cts) of the Italian Medicines Agency (Aifa), in today’s meeting, approved the use of the Nuvaxovid vaccine, making it available in the entire indication authorized by Ema for subjects aged 18 or over. years. Vaccination involves a primary vaccination course of two doses three weeks apart. This is what is stated in an Aifa note. Read also “The data available on the Nuvaxovid vaccine – notes the Cts – have shown an efficacy of about 90% in preventing symptomatic Covid-19 disease even in the population over the age of 64. The safety profile has proved positive, with mostly local adverse reactions. “We have a new vaccine, Novavax. It is another powerful weapon, with an effectiveness of over 89% to protect against symptomatic Covid “, said Giorgio Palù, president of the Italian drug agency Aifa.